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ABSTRACT 
In this paper, we provide guidance on how standard safety analyses and reporting of 
clinical trial safety data may need to be modified, given the potential impact of the 
COVID-19 pandemic.  The impact could include missed visits, alternative methods for 
assessments (such as virtual visits), alternative locations for assessments (such as local 
labs), and study drug interruptions.  We focus on safety planning for Phase 2-4 clinical 
trials and integrated summaries for submissions.  Starting from the recommended safety 
analyses proposed in white papers and a workshop, created as part of an FDA/PHUSE 
collaboration (PHUSE 2013, 2015, 2017, 2019), we assess what modifications might be 
needed. 
Impact from COVID-19 will likely affect treatment arms equally, so analyses of adverse 
events from controlled data can, to a large extent, remain unchanged.  However, 
interpretation of summaries from uncontrolled data (summaries that include open-label 
extension data) will require even more caution than usual.  Special consideration will be 
needed for safety topics of interest, especially events expected to have a higher 
incidence due to a COVID-19 infection or due to quarantine or travel restrictions (e.g., 
depression).  Analyses of laboratory measurements may need to be modified to account 
for the combination of measurements from local and central laboratories.   
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1 INTRODUCTION 
The pandemic of coronavirus disease (COVID-19) has had broad impact on ongoing 
clinical trials.  Guidance has been released by various organizations and regulatory 
agencies, e.g., Association of Clinical Research Organizations (2020), European 
Medicines Agency (2020a, 2020b), McDermott and Newman (2020), U.S. Food and 
Drug Administration (2020) to address some of the challenges.  As indicated by these 
guidance documents, challenges may arise from quarantines, site closures, travel 
limitations, or other considerations if site personnel or trial subjects become infected 
with COVID-19 conditions.  These challenges may lead to difficulties in meeting 
protocol-specified procedures, including administering or using the investigational 
product or adhering to protocol-mandated visits and laboratory/diagnostic testing.  
Thus, study drug interruptions could be more common and longer in duration, and 
missed visits and patient discontinuations could be more common.  Alternative methods 
for safety assessment could be implemented, e.g., phone contact, virtual visits, 
alternative locations for assessment (including local labs or imaging centres), that lead 
to differences in how patient information is received and recorded.  The method of 
obtaining information should be considered carefully as there may be limitations in 
interpretation depending on the collection approach (PHUSE 2017).     
PHUSE (2013, 2015, 2017, 2018, 2019), in a collaborative effort with the FDA 
(Rosario et al. 2012), has provided recommendations for standard safety analyses for 
clinical study reports and integrated submissions, contained in a collection of white 
papers and a workshop.  One of the primary purposes of the standard safety analyses is 
to identify adverse events or changes in laboratory measurements, vital signs, or ECGs 
that require further scrutiny for adverse drug reaction (ADR) determination.  ADRs are 
undesirable effects reasonably likely to be caused by a study drug.  The standard safety 
analyses provide key information when determining ADRs for the investigational 
product, but are not the only factors (CIOMS Working Groups III and V 1999, CIOMS 
Working Group VI 2005, PHUSE 2019).   
Using these standard safety analyses as a framework, in this paper, we examine the 
potential impact of COVID-19 on the scientific evaluation of safety data from clinical 
trials overlapping in time and geography with the pandemic.  Guidance is provided on 
how to simply and properly reframe the analyses.  We have chosen the 
recommendations from PHUSE white papers and workshop as our starting point, as 
they likely reflect the types of analyses that are planned for many ongoing studies.  
Whether or not product teams have implemented plans in accordance with the PHUSE 
recommendations, the principles should still apply.   
The scope of this paper is most applicable for Phase 2-4 ongoing clinical trials in 
indications unrelated to infections and respiratory diseases.  Specific issues related to 
anti-infectives and respiratory drugs, and studies that are launching now to treat the 
COVID-19 infection itself are out-of-scope. 
We understand that these extraordinary circumstances might provoke additional 
interesting questions.  For example, are there differences in event reporting by patients 
in virtual visits versus live visits?  However, for clinical study reports and submissions, 
we recommend against reporting of analyses that would distract from the main focus of 
establishing the safety profile of investigational product.   
We recognize that when assessing the potential impact of COVID-19 on standard safety 
analyses, discussion could evolve to consider updating safety planning to use the 
estimand framework (Unkel et al. 2019) if not already incorporated, and/or to use 
alternative methods proposed in recent literature e.g., Unkel et al. (2019), Stegherr et al. 
(2019) and references therein.  Unless modifications are needed to address 
insufficiencies in the current statistical analysis plans, we recommend against making 
major changes.    
This paper has been prepared by statisticians to meet the emergent need to provide 
guidance on how to reframe the most common analyses of clinical safety data that may 
have been impacted by the COVID-19 pandemic.  A follow-on paper may be prepared 
to provide additional details and considerations. 
2 DATA COLLECTION ASSUMPTIONS 
This paper is not intended to provide details on modifications to data collection that 
might be needed in ongoing studies impacted by COVID-19.  However, we do make the 
following assumptions: 
• There will be a way to identify patients who have visits impacted by COVID-19 
and the way in which patients are identified will be included in the Statistical 
Analysis Plan for the study. 
• If patients cannot attend visits due to infection, quarantine, or travel restrictions, 
key safety data collection (adverse events [AEs], serious adverse events [SAEs], 
critical labs) will continue through alternative means (such as through phone 
contacts, virtual visits, and local labs).  In the case that a longer-than-usual time 
elapsed since safety data were collected, patients may remember fewer AEs, but 
should remember the most impactful events. 
For recommendations on how to represent data changes in studies impacted by COVID-
19, consult the Clinical Data Interchange Standards Consortium (CDISC) COVID-19 
interim guide 
(https://wiki.cdisc.org/display/COVID19/CDISC+Interim+User+Guide+for+COVID-
19).  
3 ASSESSING COVID-19 IMPACT  
As noted earlier, multiple sources have examined the potential impacts of COVID-19 
upon clinical trial data.  Generally speaking, the biggest impacts are due to quarantines 
and stay-in-place orders leading to additional discontinuations, missing data due to 
missed visits, treatment interruptions, or procedures performed differently to enable 
remote assessments. 
In evaluating safety data, a fundamental concern is whether there are any variables that 
might apply differentially across treatment groups, in a way that could influence the 
conclusions.  Such variables include patient characteristics (such as sex, age, race) but 
also include aspects of study conduct (such as discontinuations, missed visits, protocol 
deviations, number of missed doses).  For example, discontinuations should be 
examined, and not only with regard to proportions of discontinuations in each treatment 
group, but also with respect to any patterns in timing of discontinuations and followup 
time.  The potential impact of any differences should be considered.   
In the context of characterizing impacts from COVID-19, evaluation of these patient 
characteristics and other aspects still are relevant and appropriate.  However, additional 
evaluations may be warranted, such as assessing the proportion of patients in some way 
impacted by COVID-19 and the proportion of visits performed remotely rather than in 
person, in order to decide if there are meaningful differences across treatment groups.   
The general expectation is that, while impacted patients may differ from patients not 
impacted, that there would not be any considerable differences among treatment groups 
in these characteristics.   
To summarize, additional analyses may need to be performed in order to make 
decisions about the adequacy of current plans.  In many cases, COVID-19 will have 
impacted each treatment arm similarly and the originally planned safety analyses may 
proceed without modification, at least for the purposes of identifying ADRs.  For 
estimation of incidence of events, additional methods may be needed, depending on the 
extent of the missing data. (See Sections 5.2 and 9 for further information).  
4 GENERAL SUMMARY OF CONCOMITANT MEDICATIONS  
As noted in PHUSE 2018, it is recommended to summarize concomitant medication use 
between treatment arms.  The primary purpose of this summary is to assess whether 
there is an imbalance between concomitant medications among treatments that would be 
important to consider when reviewing adverse event summaries.  With the COVID-19 
pandemic, it’s quite likely that there would be changes in the concomitant medication 
use.  However, since the focus on this summary is to detect imbalances, the planned 
summary and associated purpose does not need to change.  A separate summary of 
medications used to treat COVID-19 would generally not be warranted. 
5  GENERAL ANALYSES OF ADVERSE EVENTS  
5.1 Comparing percentages between treatments   
As noted in PHUSE (2017), for fixed-duration studies with similar distribution of 
follow-up times among treatment groups, comparing percentages of patients with 
specific treatment-emergent adverse events (TEAEs), SAEs, and AEs leading to study 
drug discontinuation among treatment arms (such as for investigational product versus 
placebo) is generally useful and commonly planned for helping to decide whether an 
event is an ADR.  The intent of these analyses is to assess the imbalance between 
treatment arms and the magnitude of effect, which are 2 of several important factors to 
consider when deciding if an event is an ADR (Crowe et al. 2013, Ma et al. 2015, 
PHUSE 2019).  If substantially more study patients discontinue study or study treatment 
during the controlled period in one treatment arm versus another, then different 
analytical approaches are needed.  See Section 10.9 of PHUSE (2017) and Stegherr et 
al. (2019) (and the references therein) for a discussion of pitfalls of percentage-based 
methods and possible alternative methods.  With the COVID-19 pandemic, it can be 
expected that more patients will discontinue early or have periods in which study drug 
has been interrupted.  Unless the impact is considerably different across treatment arms, 
analytical plans can generally remain unchanged.  
5.2 Summarizing Event Data without a Control    
Within statistical analysis plans for safety, there are often plans to summarize counts 
and percentages and/or exposure-adjusted incidence rates (EAIRs) for adverse events 
for the investigational product, without a control arm.  This is common for studies with 
an extension period or extension studies.  Generally, the intent of these summaries is to 
provide an easy way to identify some of the rarer events that might require case review.  
These summaries are not usually used for any comparisons.  If they are used for 
comparisons, caution is required.  This would be true even before introducing any issues 
arising due to the COVID-19 pandemic.  With the COVID-19 pandemic, the issues 
associated with comparing uncontrolled data to other sources might be exaggerated.  
For example, with the COVID-19 pandemic, there could be a substantial amount of time 
in which patients are off investigational product (e.g., during a quarantine).  Percentages 
and EAIRs could therefore be under-estimated.  As another example, percentages and 
EAIRs may be impacted due to differences in ascertainment of adverse events (e.g., 
phone call instead of a site visit).  Additionally, events associated with COVID-19 (e.g., 
fever, cough) or events associated with physical or social isolation (e.g., depression) 
might appear at a more frequent rate.  Consequently, comparing an EAIR from 
studies/integrated summaries impacted by COVID-19 with an EAIR from the literature 
or other source could be even more problematic than usual.  When it is necessary to 
compare an EAIR with another source to use as a background rate, summarizing up to 
COVID-19 impact or by COVID-19 subgroups (such as patients without impact and 
patients with impact) might be helpful for ADR decision-making.   
6 GENERAL ANALYSES OF LABORATORY DATA 
When a central lab is normally used for a study and local labs are subsequently used due 
to COVID-19, this is an important impact of COVID-19 to consider.  This situation can 
occur if patients are unable to attend a site visit (for example, the site is at a hospital that 
is closed to clinical trial activities) but are able to go to a different location for select 
laboratory measurements needed for safety monitoring. 
If a local lab is sometimes used but the measurements are not brought into the study 
database, then analyses using central lab data will be conducted with less complete data 
than what would have otherwise been available.  (As noted in Section 2, we assume that 
we will have laboratory data for critical labs).  Since analyses using central lab data will 
be incomplete, interpretation may need to rely on a combination of analyses based on 
lab measurements and adverse event summaries to a greater degree than usual.   
If a local lab is used and the measurements are brought into the study database, then 
analytical plans for central tendency analyses will need to be updated to provide clarity 
on if and when local lab measurements and central lab measurements will be combined.  
For many lab analytes, combining local and central labs could help fill in the gaps, 
providing more complete data.  However, for some analytes, directly combining the 
data may not be appropriate. Note, even when combining local and central labs, 
additional variability and uncertainty can be added into the data.  See Section 6.2 for 
more details.   
6.1 Comparing percentages of shifts to high/low between treatments   
As noted in PHUSE (2015), comparing percentages of patients shifting from 
normal/low to high and normal/high to low (sometimes referred to as treatment-
emergent highs and lows) among treatment arms is recommended.  Similar to 
comparing percentages for adverse event data, the intent of these analyses is to assess 
the imbalance among treatment arms.  As discussed in Section 3, with the COVID-19 
pandemic, perhaps more patients will discontinue early or have periods in which study 
drug has been interrupted, however, the impact will likely be similar across treatment 
arms.  Thus, analytical plans can mostly remain unchanged.  For these summaries, 
combining measurements from local labs and central labs is generally appropriate, as 
long as the limits from the associated lab are used. 
6.2 Boxplots by visit with simple summary statistics 
As noted in PHUSE (2013), summarizing changes over time by treatment using simple 
statistics via boxplots is recommended for individual studies.  Using simple summary 
statistics could be problematic if data collection is impacted by COVID-19.  During the 
pandemic there could be a substantial number of missed visits.  Under these 
circumstances, reporting means based on a mixed model for repeated measures 
(MMRM) instead of simple means may be more appropriate.  Moreover, if a local 
laboratory is used and the measurements are brought into the study database, the study 
team will need to decide which laboratory measurements can be combined.  
Alternatively, study teams can choose a different analytical approach that allows for 
combining laboratory measurements from different laboratories.  See Section 6.2.4 from 
PHUSE (2013).   
6.3 Comparing changes to minimum/maximum values between treatments 
As noted in PHUSE (2013), comparing change to a minimum/maximum value between 
treatments is generally recommended for integrated summaries.  As with comparing 
percentages between treatments, comparing changes to minimum/maximum values 
between treatments should be appropriate, unless the average number of measurements 
is very different among treatment arms.  If local labs are used and the measurements are 
brought into the study database, the same considerations described in Section 6.2 apply 
for these analyses. 
6.4 Hepatotoxicity  
Typically, in submissions, there is an expectation to assess the potential for drug-
induced hepatic injury (FDA 2009).  As part of this evaluation, a plot of alanine 
aminotransferase (ALT) versus total bilirubin is often created (Senior 2014).  The upper 
right quadrant (>3X ULN ALT, >2X ULN total bilirubin) is usually referred to as “Hy’s 
Law Range” or “Potential Hy’s law cases”.  Identification of true Hy’s Law cases 
require additional considerations, but this plot can be used to graphically show whether 
a study drug has the potential to cause hepatic injury.  For this assessment, every 
occasion of having an ALT >3X ULN and total bilirubin >2X ULN matters.  If local 
labs are used and data are not brought into the study database, there’s a potential for 
missing patients that would otherwise have been in the Hy’s Law Quadrant.  Careful 
review of adverse event data would be required.  Certainly, it would be better if all the 
results for hepatic enzymes are brought into the study database.  If local labs are used 
and data are brought into the study database, the limits from the local laboratory should 
be used to determine the multiple of the upper limit of normal. 
7 INTRINSIC FACTORS 
For large individual studies and integrated summaries of safety, there are often plans to 
summarize percentages of common TEAEs by subgroups.  These subgroups usually 
include gender, age categories, and race.  Additional subgroups may be added 
depending on the indication under study.  See Figure 12.2 of PHUSE (2017).  
Summarizing by COVID-19 subgroups for common TEAEs or other general safety 
outcomes will generally not be informative for ADR decision-making and are 
unnecessary.   
8 CASE REVIEWS 
In addition to assessing imbalances with a control and magnitude of effect, ADR 
determination includes several other factors, including impressiveness of individual 
cases.  Case reviews are conducted to assess the potential relationship with 
investigational product versus a concomitant medication versus other conditions the 
patient may be experiencing.  It’s common to create individual patient displays (such as 
narratives and graphical patient profiles) to facilitate this review.  These displays 
usually include demographics, study drug exposure, concomitant medications, AEs, 
labs, vital signs, and – when applicable – ECGs.  For exposure, it’s common to show 
start and stop dates of study drug.  If study drug has been interrupted due to a COVID-
19 quarantine or other reason, this should be reflected.  If a visit has been impacted by 
COVID-19 in any manner, this should be reflected.  Knowing dates for study drug 
exposure and knowing whether visits have been impacted in any manner would be 
helpful for these case reviews. 
9 SAFETY TOPICS OF INTEREST 
While analytical planning for general safety assessment can largely remain the same 
(with some exceptions), special consideration is needed for safety topics of interest, 
particularly those that could have a higher incidence due to COVID-19 infection or due 
to the physical or social isolation caused by mandates to stay at home (depression, for 
example).  The cross-disciplinary team should discuss the possibility for additional or 
alternative methods that might be warranted.  For example, summaries up to COVID-19 
impact or by COVID-19 subgroups for some safety topics of interest are likely 
warranted.  Additionally, more complex methodology (such as Kaplan Meier plots, Cox 
proportional hazards methods, and/or competing risk models) may need to be 
implemented.  The need for additional methods will depend on the safety topic of 
interest and the extent of the COVID-19 impact (and impact from other factors).  If 
choosing across alternative methods, it is important to try to connect the method with 
the eventual interpretation, and to understand the pros and cons of the methodological 
choices.  A full discourse on these methods is beyond the scope of this paper.  
Nevertheless, we offer some insights on one particular methodology, namely, 
competing risks.  COVID-19 logistical problems are unlikely to introduce a need for 
competing risk analysis for a study for which no competing risk analysis was needed 
prior to the COVID-19 pandemic, unless a study has many deaths from COVID-19 
infection.  Competing risks are events that preclude or greatly alter the occurrence of the 
main event of interest.  For example, if the event of interest is myocardial infarction, 
death from other causes would be considered a competing risk.  Competing risks are 
different from other concurrent events in that they actually preclude the event of interest 
from happening, whereas events like early study discontinuation prevent the event from 
being observed.  Various authors, e.g., Allignol et al. (2016), Bender et al. (2016), 
Geskus (2016), Hengelbrock et al. (2016), Proctor and Schumacher (2016), Unkel et al. 
(2019) have written about the need to consider competing risks in the assessment of the 
risk/probability of adverse events.  As noted by Allison (2018), standard Kaplan Meier 
or Cox proportional hazards methods perform better for determining whether or not the 
drug is causally related to the AE than methods that take into account the competing 
risk.  Alternatively, if interest is in getting an accurate percentage of patients with the 
event (as for the product label), estimation methods that take competing risks into 
account may be useful.   
For some compounds, such as those used to treat auto-immune conditions, infections 
might already be a safety topic of interest.  For these compounds and possibly others, 
considering the COVID-19 infection itself as a safety topic of interest could be 
warranted.  This could arise if there is biological plausibility for a greater risk for 
infection and/or if there is imbalance in COVID-19 infections between treatment arms.  
Additional analyses that might be needed in this situation are out-of-scope, but would 
likely follow similar approaches to any safety topic of interest. 
10 PRODUCT LABELING 
For product labeling purposes, additional displays are often needed to characterize 
ADRs.  These often include an assessment of event duration or whether a change in 
labs/vitals is transient versus persistent.  With the COVID-19 pandemic, it’s possible 
that less information will be available to assess these patterns in the data due to missing 
visits, early study discontinuation, early study drug discontinuation, or study drug 
interruption.  Using group means to assess transient (versus persistent) patterns always 
has the potential to be misleading (PHUSE 2019), but the potential is even greater if 
discontinuations or interruptions are more common.  Thus, for these assessments, using 
a display that graphically displays individual patient data is recommended.  For events, 
see Appendix B in (PHUSE 2017) for an example of a plot showing events over time 
(onset and duration).  For labs/vitals, a spaghetti plot (plot of values [vertical axis] 
versus time [horizontal axis] and connecting the dots chronologically with lines for each 
patient) serves this purpose.  In a spaghetti plot, symbols or color can be used for when 
a patient is on or off drug. 
When communicating about ADRs in labeling, cautionary language on the limitations 
of comparing with other labels is usually included.  For compounds in which there is a 
large impact from COVID-19, the cautionary language may need to be expanded to 
mention the potential for under- or over-reporting due to COVID-19. Furthermore, 
depending on the rarity of the event and the extent of COVID-19 impact on the study, 
it’s possible that it would be more appropriate to use a percentage from the non-
COVID-impacted group.  It may be useful to have these available.   
11 SUMMARY OF SAFETY EVALUATION  
Table 1 provides a summary of the recommendations that are applicable for most 
situations.  However, the details in previous sections are needed to fully understand the 
recommendations, possible exceptions, and cautionary notes.  The analysis type 
included in this table are from select analyses described in the PHUSE white papers. 
Table 1.  Summary of recommendations for common safety analyses (as recommended by 
PHUSE white papers and safety workshop (PHUSE 2013, 2015, 2017, 2018, 2019)) for clinical 
trials impacted by COVID-19 
Analysis Type Recommendation for updating analysis 
plan 
Concomitant medications - Comparing 
percentages between treatments 
Likely no change needed 
TEAEs, SAEs, AEs leading to study drug 
discontinuation - comparing percentages 
between treatments 
For general safety summaries, likely no 
change needed 
TEAEs for uncontrolled data – 
Summarizing counts, percentages, 
exposure-adjusted incidence rates 
For general safety summaries, likely no 
change needed 
Labs/vitals – Comparing percentages 
between treatments (e.g., treatment-
emergent highs and lows) 
No change needed, except if data from 
local labs are included in the clinical trial 
database, low/normal/high should be 
determined using the local lab reference 
limits 
Labs/vitals - Boxplots by visit with simple 
summary statistics under the boxplot  
(recommended for individual studies) 
If COVID-19 impact includes a lot of 
missed visits, consider reporting means 
based on MMRM instead of the simple 
mean under the boxplot.  If data from 
local labs are included in the clinical trial 
database, a decision is needed on which 
lab analytes can use combined data 
versus not or change to an alternative 
method that allows for the combination 
Labs/vitals - Comparing mean change to 
minimum/maximum values between 
No change needed, except if data from 
local labs are included in the clinical trial 
database, a decision is needed on which 
treatments (recommended for 
integrated summaries) 
lab analytes can use combined data 
versus not or change to an alternative 
method that allows for the combination 
Hepatotoxicity – Plot of alanine 
aminotransferase versus total bilirubin 
If local labs are used and data are not 
brought into the study database, there’s 
a potential for missing patients that 
would otherwise have been in the Hy’s 
Law Quadrant.  Careful review of 
adverse event data would be required.  
If local labs are used and data are 
brought into the study database, use the 
limits from the local lab to determine 
the multiple of the upper limit of 
normal. 
Intrinsic Factors:  Subgroup analyses for 
common TEAEs  
Likely no change needed  
Case reviews Include study drug exposure start/stop 
dates and information on visits impacted 
by COVID-19 
Safety topics of interest For safety topics of interest that could 
have a higher incidence due to COVID-19 
infection or due to the physical or social 
isolation caused by mandates to stay at 
home , summarizing by COVID-19 
subgroups (e.g., patients without 
impact, patients with impact) might be 
helpful for ADR decision-making. 
ADR characterization in product labeling 
(e.g., event duration, transient versus 
persistent assessment) 
If group summaries are planned, 
consider replacing with patient-based 
displays 
ADR communication (e.g., percentages to 
report) in product labeling 
If the COVID-19 impact is large, for some 
ADRs, reporting the percentage from the 
non-COVID-impacted group might be 
warranted.  Cautionary language may 
need to mention the potential for under- 
or over-reporting due to COVID-19. 
 
12 CONCLUDING REMARKS 
For general assessment of AEs, SAEs, and AEs leading to permanent discontinuation of 
study drug (for controlled data), we believe analysis plans can largely remain 
unchanged unless COVID-19 logistics introduce differential observation time between 
treatments.  For safety topics of interest expected to have a higher incidence due to a 
COVID-19 infection or due to quarantine or stay-at-home mandates (such as for 
depression), comparing exposure-adjusted incidence rates from uncontrolled data with a 
background rate from literature or alternative source could be more problematic than 
usual.  For such safety topics, limiting data up to COVID-19 impact or summarizing by 
COVID-19 subgroups (for example, patients who had study visits impacted by COVID-
19 versus patients who did not have any study visits impacted by COVID-19) should be 
considered.  Conducting general safety analyses by COVID-19 subgroups does not 
seem warranted.  For analyses of laboratory measurements, analysis plans will likely 
need to be updated if there is a combination of measurements from local labs and 
central labs in the study database.  When communicating ADRs in labelling, cautionary 
language on the limitations of comparing with other labels may need to be expanded to 
mention the potential for under- or over-reporting due to COVID-19 impact. 
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